APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vigabatrin

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Vigabatrin Industry Growth and Trends Forecast to 2032

Report ID 174046280120 December 2025101 pages

Choose your research edition.

Industry ResearchVigabatrin Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Vigabatrin Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Vigabatrin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vigabatrin Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Vigabatrin Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Vigabatrin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Vigabatrin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Vigabatrin is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vigabatrin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vigabatrin include Sanofi, Novartis, Upsher-Smith, Perrigo, Lundbeck, Grindeks, Endo International, Dr. Fisher Farma and Cipla, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Vigabatrin market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Vigabatrin market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Vigabatrin market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Vigabatrin.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Vigabatrin market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Vigabatrin Market by Company

Sanofi

Novartis

Upsher-Smith

Perrigo

Lundbeck

Grindeks

Endo International

Dr. Fisher Farma

Cipla

Benta Pharma Industries

Amneal Pharma

Vigabatrin Segment by Type

Tablet

Powder

Vigabatrin Segment by Application

Partial-Onset Seizures

Refractory Complex Partial Seizures

Infantile Spasms (IS)

Vigabatrin Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vigabatrin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vigabatrin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vigabatrin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vigabatrin manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Vigabatrin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Tablet Table 2. Major Company of Powder Table 3. Global Vigabatrin Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Vigabatrin Sales by Type (2021-2026) & (K Units) Table 5. Global Vigabatrin Sales Market Share in Volume by Type (2021-2026) Table 6. Global Vigabatrin Sales by Type (2021-2026) & (US$ Million) Table 7. Global Vigabatrin Sales Market Share in Value by Type (2021-2026) Table 8. Global Vigabatrin Price by Type (2021-2026) & (US$/Unit) Table 9. Global Vigabatrin Sales by Type (2027-2032) & (K Units) Table 10. Global Vigabatrin Sales Market Share in Volume by Type (2027-2032) Table 11. Global Vigabatrin Sales by Type (2027-2032) & (US$ Million) Table 12. Global Vigabatrin Sales Market Share in Value by Type (2027-2032) Table 13. Global Vigabatrin Price by Type (2027-2032) & (US$/Unit) Table 14. North America Vigabatrin Sales by Type (2021-2026) & (K Units) Table 15. North America Vigabatrin Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Vigabatrin Sales by Type (2021-2026) & (K Units) Table 17. Europe Vigabatrin Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Vigabatrin Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Vigabatrin Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Vigabatrin Sales by Type (2021-2026) & (K Units) Table 21. Latin America Vigabatrin Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Vigabatrin Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Vigabatrin Sales by Type (2021-2026) & (US$ Million) Table 24. Vigabatrin Industry Trends Table 25. Vigabatrin Industry Drivers Table 26. Vigabatrin Industry Opportunities and Challenges Table 27. Vigabatrin Industry Restraints Table 28. Global Vigabatrin Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Vigabatrin Revenue Market Share by Company (2021-2026) Table 30. Global Vigabatrin Sales by Company (2021-2026) & (K Units) Table 31. Global Vigabatrin Sales Share by Company (2021-2026) Table 32. Global Vigabatrin Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Vigabatrin Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Vigabatrin Major Company Production Sites and Headquarters Table 35. Global Vigabatrin Company, Product Type & Application Table 36. Global Vigabatrin Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Vigabatrin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Vigabatrin Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Vigabatrin Sales by Region (2021-2026) & (K Units) Table 41. Global Vigabatrin Sales Market Share in Volume by Region (2021-2026) Table 42. Global Vigabatrin Sales by Region (2021-2026) & (US$ Million) Table 43. Global Vigabatrin Sales Market Share in Value by Region (2021-2026) Table 44. Global Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Vigabatrin Sales by Region (2027-2032) & (K Units) Table 46. Global Vigabatrin Sales Market Share in Volume by Region (2027-2032) Table 47. Global Vigabatrin Sales by Region (2027-2032) & (US$ Million) Table 48. Global Vigabatrin Sales Market Share in Value by Region (2027-2032) Table 49. Global Vigabatrin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Vigabatrin Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Vigabatrin Sales by Application (2021-2026) & (K Units) Table 52. Global Vigabatrin Sales Market Share in Volume by Application (2021-2026) Table 53. Global Vigabatrin Sales by Application (2021-2026) & (US$ Million) Table 54. Global Vigabatrin Sales Market Share in Value by Application (2021-2026) Table 55. Global Vigabatrin Price by Application (2021-2026) & (US$/Unit) Table 56. Global Vigabatrin Sales by Application (2027-2032) & (K Units) Table 57. Global Vigabatrin Sales Market Share in Volume by Application (2027-2032) Table 58. Global Vigabatrin Sales by Application (2027-2032) & (US$ Million) Table 59. Global Vigabatrin Sales Market Share in Value by Application (2027-2032) Table 60. Global Vigabatrin Price by Application (2027-2032) & (US$/Unit) Table 61. North America Vigabatrin Sales by Application (2021-2026) & (K Units) Table 62. North America Vigabatrin Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Vigabatrin Sales by Application (2021-2026) & (K Units) Table 64. Europe Vigabatrin Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Vigabatrin Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Vigabatrin Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Vigabatrin Sales by Application (2021-2026) & (K Units) Table 68. Latin America Vigabatrin Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Vigabatrin Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Vigabatrin Sales by Application (2021-2026) & (US$ Million) Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Sanofi Vigabatrin Product Portfolio Table 75. Sanofi Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Novartis Vigabatrin Product Portfolio Table 80. Novartis Recent Development Table 81. Upsher-Smith Company Information Table 82. Upsher-Smith Business Overview Table 83. Upsher-Smith Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Upsher-Smith Vigabatrin Product Portfolio Table 85. Upsher-Smith Recent Development Table 86. Perrigo Company Information Table 87. Perrigo Business Overview Table 88. Perrigo Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Perrigo Vigabatrin Product Portfolio Table 90. Perrigo Recent Development Table 91. Lundbeck Company Information Table 92. Lundbeck Business Overview Table 93. Lundbeck Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Lundbeck Vigabatrin Product Portfolio Table 95. Lundbeck Recent Development Table 96. Grindeks Company Information Table 97. Grindeks Business Overview Table 98. Grindeks Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Grindeks Vigabatrin Product Portfolio Table 100. Grindeks Recent Development Table 101. Endo International Company Information Table 102. Endo International Business Overview Table 103. Endo International Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Endo International Vigabatrin Product Portfolio Table 105. Endo International Recent Development Table 106. Dr. Fisher Farma Company Information Table 107. Dr. Fisher Farma Business Overview Table 108. Dr. Fisher Farma Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Dr. Fisher Farma Vigabatrin Product Portfolio Table 110. Dr. Fisher Farma Recent Development Table 111. Cipla Company Information Table 112. Cipla Business Overview Table 113. Cipla Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Cipla Vigabatrin Product Portfolio Table 115. Cipla Recent Development Table 116. Benta Pharma Industries Company Information Table 117. Benta Pharma Industries Business Overview Table 118. Benta Pharma Industries Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Benta Pharma Industries Vigabatrin Product Portfolio Table 120. Benta Pharma Industries Recent Development Table 121. Amneal Pharma Company Information Table 122. Amneal Pharma Business Overview Table 123. Amneal Pharma Vigabatrin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Amneal Pharma Vigabatrin Product Portfolio Table 125. Amneal Pharma Recent Development Table 126. North America Vigabatrin Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 127. North America Vigabatrin Sales by Country (2021-2026) & (K Units) Table 128. North America Vigabatrin Sales Market Share by Country (2021-2026) Table 129. North America Vigabatrin Sales Forecast by Country (2027-2032) & (K Units) Table 130. North America Vigabatrin Sales Market Share Forecast by Country (2027-2032) Table 131. North America Vigabatrin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. North America Vigabatrin Market Size by Country (2021-2026) & (US$ Million) Table 133. North America Vigabatrin Market Share by Country (2021-2026) Table 134. North America Vigabatrin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. North America Vigabatrin Market Share Forecast by Country (2027-2032) Table 136. Europe Vigabatrin Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. Europe Vigabatrin Sales by Country (2021-2026) & (K Units) Table 138. Europe Vigabatrin Sales Market Share by Country (2021-2026) Table 139. Europe Vigabatrin Sales Forecast by Country (2027-2032) & (K Units) Table 140. Europe Vigabatrin Sales Market Share Forecast by Country (2027-2032) Table 141. Europe Vigabatrin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Europe Vigabatrin Market Size by Country (2021-2026) & (US$ Million) Table 143. Europe Vigabatrin Market Share by Country (2021-2026) Table 144. Europe Vigabatrin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Europe Vigabatrin Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Vigabatrin Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Vigabatrin Sales by Country (2021-2026) & (K Units) Table 148. Asia-Pacific Vigabatrin Sales Market Share by Country (2021-2026) Table 149. Asia-Pacific Vigabatrin Sales Forecast by Country (2027-2032) & (K Units) Table 150. Asia-Pacific Vigabatrin Sales Market Share Forecast by Country (2027-2032) Table 151. Asia-Pacific Vigabatrin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Asia-Pacific Vigabatrin Market Size by Country (2021-2026) & (US$ Million) Table 153. Asia-Pacific Vigabatrin Market Share by Country (2021-2026) Table 154. Asia-Pacific Vigabatrin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Asia-Pacific Vigabatrin Market Share Forecast by Country (2027-2032) Table 156. Latin America Vigabatrin Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 157. Latin America Vigabatrin Sales by Country (2021-2026) & (K Units) Table 158. Latin America Vigabatrin Sales Market Share by Country (2021-2026) Table 159. Latin America Vigabatrin Sales Forecast by Country (2027-2032) & (K Units) Table 160. Latin America Vigabatrin Sales Market Share Forecast by Country (2027-2032) Table 161. Latin America Vigabatrin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Latin America Vigabatrin Market Size by Country (2021-2026) & (US$ Million) Table 163. Latin America Vigabatrin Market Share by Country (2021-2026) Table 164. Latin America Vigabatrin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Latin America Vigabatrin Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Vigabatrin Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Vigabatrin Sales by Country (2021-2026) & (K Units) Table 168. Middle East and Africa Vigabatrin Sales Market Share by Country (2021-2026) Table 169. Middle East and Africa Vigabatrin Sales Forecast by Country (2027-2032) & (K Units) Table 170. Middle East and Africa Vigabatrin Sales Market Share Forecast by Country (2027-2032) Table 171. Middle East and Africa Vigabatrin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Middle East and Africa Vigabatrin Market Size by Country (2021-2026) & (US$ Million) Table 173. Middle East and Africa Vigabatrin Market Share by Country (2021-2026) Table 174. Middle East and Africa Vigabatrin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Middle East and Africa Vigabatrin Market Share Forecast by Country (2027-2032) Table 176. Key Raw Materials Table 177. Raw Materials Key Suppliers Table 178. Vigabatrin Distributors List Table 179. Vigabatrin Customers List Table 180. Research Programs/Design for This Report Table 181. Authors List of This Report Table 182. Secondary Sources Table 183. Primary Sources List of Figures Figure 1. Vigabatrin Image Figure 2. Global Vigabatrin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vigabatrin Market Size (2021-2032) & (US$ Million) Figure 4. Global Vigabatrin Sales (2021-2032) & (K Units) Figure 5. Tablet Image Figure 6. Global Tablet Sales YoY Growth (2021-2032) & (K Units) Figure 7. Powder Image Figure 8. Global Powder Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Vigabatrin Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Vigabatrin Market Share by Type 2025 VS 2032 Figure 11. North America Vigabatrin Sales Market Share in Volume by Type in 2025 Figure 12. North America Vigabatrin Sales Market Share in Value by Type in 2025 Figure 13. Europe Vigabatrin Sales Market Share in Volume by Type in 2025 Figure 14. Europe Vigabatrin Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Vigabatrin Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Vigabatrin Sales Market Share in Value by Type in 2025 Figure 17. Latin America Vigabatrin Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Vigabatrin Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Vigabatrin Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Vigabatrin Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Vigabatrin Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Partial-Onset Seizures Image Figure 24. Global Partial-Onset Seizures Sales YoY Growth (2021-2032) & (K Units) Figure 25. Refractory Complex Partial Seizures Image Figure 26. Global Refractory Complex Partial Seizures Sales YoY Growth (2021-2032) & (K Units) Figure 27. Infantile Spasms (IS) Image Figure 28. Global Infantile Spasms (IS) Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Vigabatrin Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Vigabatrin Market Share by Application 2025 VS 2032 Figure 31. North America Vigabatrin Sales Market Share in Volume by Application in 2025 Figure 32. North America Vigabatrin Sales Market Share in Value by Application in 2025 Figure 33. Europe Vigabatrin Sales Market Share in Volume by Application in 2025 Figure 34. Europe Vigabatrin Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Vigabatrin Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Vigabatrin Sales Market Share in Value by Application in 2025 Figure 37. Latin America Vigabatrin Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Vigabatrin Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Vigabatrin Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Vigabatrin Sales Market Share in Value by Application in 2025 Figure 41. North America Vigabatrin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Vigabatrin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Vigabatrin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Vigabatrin Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Vigabatrin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Vigabatrin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Vigabatrin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Vigabatrin Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Vigabatrin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Vigabatrin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Vigabatrin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Vigabatrin Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Vigabatrin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Vigabatrin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Vigabatrin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Vigabatrin Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Vigabatrin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Vigabatrin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Vigabatrin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Vigabatrin Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Vigabatrin Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Vigabatrin Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Tablet
  • Powder
Applications
  • Partial-Onset Seizures
  • Refractory Complex Partial Seizures
  • Infantile Spasms (IS)
Companies covered
  • Sanofi
  • Novartis
  • Upsher-Smith
  • Perrigo
  • Lundbeck
  • Grindeks
  • Endo International
  • Dr. Fisher Farma
  • Cipla
  • Benta Pharma Industries
  • Amneal Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vigabatrin Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Vigabatrin Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Vigabatrin Market by Type
  6. 1.3.1 Tablet
  7. 1.3.2 Powder
  8. 1.4 Global Vigabatrin Market Size by Type
  9. 1.4.1 Global Vigabatrin Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Vigabatrin Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Vigabatrin Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Vigabatrin Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Vigabatrin Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Vigabatrin Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Vigabatrin Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Vigabatrin Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Vigabatrin Industry Trends
  2. 2.2 Vigabatrin Industry Drivers
  3. 2.3 Vigabatrin Industry Opportunities and Challenges
  4. 2.4 Vigabatrin Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Vigabatrin Revenue (2021-2026)
  2. 3.2 Global Top Players by Vigabatrin Sales (2021-2026)
  3. 3.3 Global Top Players by Vigabatrin Price (2021-2026)
  4. 3.4 Global Vigabatrin Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vigabatrin Major Company Production Sites & Headquarters
  6. 3.6 Global Vigabatrin Company, Product Type & Application
  7. 3.7 Global Vigabatrin Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vigabatrin Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vigabatrin Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vigabatrin Tier 1, Tier 2, and Tier 3
4 Vigabatrin Regional Status and Outlook
  1. 4.1 Global Vigabatrin Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Vigabatrin Historic Market Size by Region
  3. 4.2.1 Global Vigabatrin Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Vigabatrin Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Vigabatrin Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Vigabatrin Forecasted Market Size by Region
  7. 4.3.1 Global Vigabatrin Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Vigabatrin Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Vigabatrin Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Vigabatrin by Application
  1. 5.1 Vigabatrin Market by Application
  2. 5.1.1 Partial-Onset Seizures
  3. 5.1.2 Refractory Complex Partial Seizures
  4. 5.1.3 Infantile Spasms (IS)
  5. 5.2 Global Vigabatrin Market Size by Application
  6. 5.2.1 Global Vigabatrin Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Vigabatrin Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Vigabatrin Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Vigabatrin Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Vigabatrin Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Vigabatrin Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Vigabatrin Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Vigabatrin Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sanofi Vigabatrin Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Vigabatrin Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Upsher-Smith
  14. 6.3.1 Upsher-Smith Company Information
  15. 6.3.2 Upsher-Smith Business Overview
  16. 6.3.3 Upsher-Smith Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Upsher-Smith Vigabatrin Product Portfolio
  18. 6.3.5 Upsher-Smith Recent Developments
  19. 6.4 Perrigo
  20. 6.4.1 Perrigo Company Information
  21. 6.4.2 Perrigo Business Overview
  22. 6.4.3 Perrigo Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Perrigo Vigabatrin Product Portfolio
  24. 6.4.5 Perrigo Recent Developments
  25. 6.5 Lundbeck
  26. 6.5.1 Lundbeck Company Information
  27. 6.5.2 Lundbeck Business Overview
  28. 6.5.3 Lundbeck Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Lundbeck Vigabatrin Product Portfolio
  30. 6.5.5 Lundbeck Recent Developments
  31. 6.6 Grindeks
  32. 6.6.1 Grindeks Company Information
  33. 6.6.2 Grindeks Business Overview
  34. 6.6.3 Grindeks Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Grindeks Vigabatrin Product Portfolio
  36. 6.6.5 Grindeks Recent Developments
  37. 6.7 Endo International
  38. 6.7.1 Endo International Company Information
  39. 6.7.2 Endo International Business Overview
  40. 6.7.3 Endo International Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Endo International Vigabatrin Product Portfolio
  42. 6.7.5 Endo International Recent Developments
  43. 6.8 Dr. Fisher Farma
  44. 6.8.1 Dr. Fisher Farma Company Information
  45. 6.8.2 Dr. Fisher Farma Business Overview
  46. 6.8.3 Dr. Fisher Farma Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Dr. Fisher Farma Vigabatrin Product Portfolio
  48. 6.8.5 Dr. Fisher Farma Recent Developments
  49. 6.9 Cipla
  50. 6.9.1 Cipla Company Information
  51. 6.9.2 Cipla Business Overview
  52. 6.9.3 Cipla Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Cipla Vigabatrin Product Portfolio
  54. 6.9.5 Cipla Recent Developments
  55. 6.10 Benta Pharma Industries
  56. 6.10.1 Benta Pharma Industries Company Information
  57. 6.10.2 Benta Pharma Industries Business Overview
  58. 6.10.3 Benta Pharma Industries Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Benta Pharma Industries Vigabatrin Product Portfolio
  60. 6.10.5 Benta Pharma Industries Recent Developments
  61. 6.11 Amneal Pharma
  62. 6.11.1 Amneal Pharma Company Information
  63. 6.11.2 Amneal Pharma Business Overview
  64. 6.11.3 Amneal Pharma Vigabatrin Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Amneal Pharma Vigabatrin Product Portfolio
  66. 6.11.5 Amneal Pharma Recent Developments
7 North America by Country
  1. 7.1 North America Vigabatrin Sales by Country
  2. 7.1.1 North America Vigabatrin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Vigabatrin Sales by Country (2021-2026)
  4. 7.1.3 North America Vigabatrin Sales Forecast by Country (2027-2032)
  5. 7.2 North America Vigabatrin Market Size by Country
  6. 7.2.1 North America Vigabatrin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Vigabatrin Market Size by Country (2021-2026)
  8. 7.2.3 North America Vigabatrin Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Vigabatrin Sales by Country
  2. 8.1.1 Europe Vigabatrin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Vigabatrin Sales by Country (2021-2026)
  4. 8.1.3 Europe Vigabatrin Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Vigabatrin Market Size by Country
  6. 8.2.1 Europe Vigabatrin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Vigabatrin Market Size by Country (2021-2026)
  8. 8.2.3 Europe Vigabatrin Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Vigabatrin Sales by Country
  2. 9.1.1 Asia-Pacific Vigabatrin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Vigabatrin Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Vigabatrin Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Vigabatrin Market Size by Country
  6. 9.2.1 Asia-Pacific Vigabatrin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Vigabatrin Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Vigabatrin Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Vigabatrin Sales by Country
  2. 10.1.1 South America Vigabatrin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Vigabatrin Sales by Country (2021-2026)
  4. 10.1.3 South America Vigabatrin Sales Forecast by Country (2027-2032)
  5. 10.2 South America Vigabatrin Market Size by Country
  6. 10.2.1 South America Vigabatrin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Vigabatrin Market Size by Country (2021-2026)
  8. 10.2.3 South America Vigabatrin Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Vigabatrin Sales by Country
  2. 11.1.1 Middle East and Africa Vigabatrin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Vigabatrin Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Vigabatrin Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Vigabatrin Market Size by Country
  6. 11.2.1 Middle East and Africa Vigabatrin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Vigabatrin Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Vigabatrin Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Vigabatrin Value Chain Analysis
  2. 12.1.1 Vigabatrin Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Vigabatrin Production Mode & Process
  7. 12.2 Vigabatrin Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Vigabatrin Distributors
  10. 12.2.3 Vigabatrin Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst